Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 4/20 | 0.62 |
| ▸ | RIPK2 | O43353 | 8/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 8/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.45 |
| ▸ | EGFR | P00533 | 5/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5109467 | 0.89 | MAPK8 (0.52) | MAPK8RIPK2NOD2ACVR1FGFR1 | |
| SCHEMBL4902177 | 0.87 | MAPK14 (0.48) | MAPK8MAPK14 | |
| SCHEMBL5113605 | 0.83 | MAPK14 (0.45) | MAPK8RIPK2NOD2MAPK14 | |
| SCHEMBL5107470 | 0.83 | MAPK14 (0.55) | MAPK8RIPK2NOD2ACVR1MAPK14 | |
| SCHEMBL29498171 | 0.81 | FGFR1 (0.69) | RIPK2NOD2ACVR1FGFR1EGFR | |
| SCHEMBL3762584 | 0.81 | FGFR1 (0.69) | RIPK2NOD2ACVR1FGFR1EGFR | |
| SCHEMBL5114375 | 0.81 | MAPK14 (0.58) | MAPK8RIPK2NOD2MAPK14 | |
| SCHEMBL5120273 | 0.80 | MAPK14 (0.57) | MAPK8MAPK14 | |
| SCHEMBL14280044 | 0.80 | FGFR1 (0.41) | MAPK8RIPK2NOD2ACVR1FGFR1 | |
| SCHEMBL31635903 | 0.79 | RIPK2 (0.45) | RIPK2NOD2ACVR1FGFR1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449581-B2 | 6-Substituted pyrido-pyrimidines | POCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449581-B2 | 6-Substituted pyrido-pyrimidines | POCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN J | 2007-06-14 | — | — | US | disclosed |
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN J | 2007-06-14 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169794-B2 | 6-substituted pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1361880-B1 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| US-20040116698-A1 | 6-Substituted pyrido-pyrimidines | CHEN JIAN JEFFREY (US) | 2004-06-17 | — | — | US | disclosed |
| US-6696566-B2 | SELECTIVE P38 KINASE INHIBITORS RELATIVE TO CYCLIN-DEPENDENT KINASES AND TYROSINE KINASES | SYNTEX (U.S.A.) LLC | 2004-02-24 | — | — | US | disclosed |
| EP-1361880-A2 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-19 | — | — | EP | disclosed |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | SYNTEX (U.S.A.) LLC | 2003-09-11 | — | — | US | disclosed |
| WO-2002064594-A2 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135458-A1 | 6-Substituted pyrido-pyrimidines | P2RX6, P2RX1, P2RX7 | MAPK8 3523/4885RIPK2 2589/4885NOD2 1781/4885 |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | ARRB1, MAPK1, MAPK8 | MAPK8 3/4885RIPK2 458/4885NOD2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.